Japan's Takeda Pharmaceutical has submitted a second post-marketing study to regulators in the United States, Europe and Japan that it says shows no increased risk of bladder cancer in patients treated with Actos (pioglitazone) in a key milestone following its April decision to settle thousands of lawsuits related to the diabetes drug.
Takeda Pharmaceutical Chairman Yasuchika Hasegawa was removed as vice president by the Japan Pharmaceutical Manufacturers Association, according to an updated leadership list that was confirmed by a company spokesman.
Takeda Pharmaceutical was sanctioned by Japan's Ministry of Health, Labor and Welfare for using exaggerated marketing materials to promote hypertension medicine Blopress and was issued a business improvement order with which it will comply, according to a June 12 press release from the company.
Takeda Pharmaceutical has consolidated vaccine offices, signed a slew of alliances for discovery efforts and moved aggressively to refocus the company since Christophe Weber took over as CEO on April 1.
A move by Takeda Pharmaceutical to consolidate its Vaccine Business Unit into hubs should allow sharper focus on a complex set of vaccine programs covering norovirus, dengue and seasonal influenza in an increasingly competitive global horse race.
Japan's Eisai, Shinogi and Takeda Pharmaceutical have teamed up with U.K.-based AstraZeneca on a broad R&D effort to find treatments for insect-borne parasitic diseases Chagas and leishmaniasis.
A tussle over the termination of a trial to assess the cardiovascular safety of obesity drug Contrave is in swing, with Orexigen Therapeutics and Takeda Pharmaceutical entering a dispute process, according to Reuters, with earlier data breaches the subject of a separate issue.
Takeda Development Center Americas, a unit of Japan's Takeda Pharmaceutical, and Orexigen Therapeutics have ended a cardiovascular outcomes trial that compared the obesity drug Contrave to a placebo in addition to diet and exercise counselling, in 8,909 overweight and obese patients with certain CV risk factors, the companies said.
Takeda Pharmaceutical and Japan's National Cancer Center have entered into a plan to find and develop anticancer agents and a way to get them to Japanese patients quickly. The plan, in part, is to build on their collaboration on a genomic screening project led by the NCC.
Sumitomo Dainippon Pharma and Takeda Pharmaceutical have canceled a four-year-old license and development agreement aimed at commercialization of lurasidone hydrochloride (Latuda) products following disappointing Phase III trials to treat schizophrenia announced last month.